Quantcast

Industry news that matters to you.  Learn more

Urine Protein Could Pave the Way for New Prostate Cancer Test

Cancer research UK scientists have shown that a protein in urine could be a powerful indicator of prostate cancer risk, according to a study published in PLoS ONE.

Scientists from the Cancer Research UK Cambridge Research Institute and The Institute of Cancer Research (ICR) built on earlier genome-wide research to link a genetic change associated with prostate cancer risk to a significant reduction in the amount of a protein called microseminoprotein-beta (MSMB). The protein – which regulates prostate cell death – is produced by normal prostate cells – and is linked to an increased risk of developing prostate cancer.

Detection of Key Epigenetic Biomarkers

Epigenetics refers to the study of heritable changes in genome function that occur without a change in the primary DNA sequence of an organism. One such change is DNA methylation, most frequently characterized by an enzymatic modification at the fifth position of cytosine (5-mC), present abundantly in the context of CpG dinucleotides. The formation and maintenance of 5-mC is catalyzed by cellular DNA (cytosine-5) methyltransferases (DNMTs).

Clinical Genomics Pty Ltd and The Garvan Institute of Medical Research Enter into Licensing Agreement

Clinical Genomics Pty. Ltd. and The Garvan Institute of Medical Research (Sydney, Australia) today announced that they have entered into a license agreement in relation to novel biomarkers discovered by scientists at the Garvan Institute. Under the terms of the agreement, Clinical Genomics obtains worldwide exclusive rights to the Garvan’s proprietary cancer associated methylation DNA biomarkers for the diagnosis and or treatment of colorectal cancer. Clinical Genomics intends to expand its colorectal biomarker research program to evaluate these promising biomarkers in view of formulating a diagnostic test utilizing those biomarkers demonstrating clinical benefit for the early detection of colorectal cancer.

OncoMethylome Sciences Signs Agreement for the Potential Use of its Technology Platform in GlaxoSmithKline Biologicals Immunotherapy Development Program

OncoMethylome Sciences, a leading molecular diagnostics company, announced today that it has entered into an agreement with GlaxoSmithKline Biologicals S.A. (GSK) for the potential use of one of its DNA methylation specific PCR biomarkers in GSKs immunotherapy development program. Additional financial details were not disclosed.

Mount Sinai Researchers Develop New Computational Method to Aide Analysis of Gene Expression Experiments

Researchers from Mount Sinai School of Medicine have developed a new computational method that will help streamline the analysis of gene expression experiments and provide scientists with a better mechanistic understanding of the differences between diseased and normal cells. The new database and software, called ChIP Enrichment Analysis (ChEA), will revolutionize how researchers identify drug targets and biomarkers. Researchers can find the tool online at http://amp.pharm.mssm.edu/lib/chea.jsp. The data are published in Bioinformatics.